Skip to main content

Together we are beating cancer

Donate now

Treatments policy

Showing 8 out of 8 results
Woman waiting in hospital waiting room

Get the latest updates and analysis on NHS cancer waiting times in England, and learn what it means for people affected by cancer Get the latest updates and analysis on NHS cancer waiting times in England, and learn what it means for people affected by cancer

by Sophia Lowes, Imogen Powell Brown | Analysis | 11 July 2024

11 July 2024

A health professional holding a patient's hand in hospital

We outline some of the highlights from our new report 'Leading on Cancer' where we set out the evidence on the role that cancer control strategies can play in improving cancer outcomes We outline some of the highlights from our new report 'Leading on Cancer' where we set out the evidence on the role that cancer control strategies can play in improving cancer outcomes

by Imogen Powell Brown | Analysis | 19 June 2024

19 June 2024

A patient receiving radiotherapy

On the back of a recent survey, our new policy position statement on radiotherapy turns patient experiences into recommendations for the Government and the NHS. On the back of a recent survey, our new policy position statement on radiotherapy turns patient experiences into recommendations for the Government and the NHS.

by Mads Thomsen | Opinion | 4 May 2023

4 May 2023

Michelle Mitchell chief executive Cancer Research UK

Cancer is a fixable problem – but we need the right leadership, a robust plan and sufficient funding, writes Michelle Mitchell, our chief executive officer. Cancer is a fixable problem – but we need the right leadership, a robust plan and sufficient funding, writes Michelle Mitchell, our chief executive officer.

by Michelle Mitchell | Opinion | 8 December 2022

8 December 2022

Various medicines in packets.

In the last decade, many more cancer drugs have become available compared to what we’ve seen previously. This has led to more cancer treatment options, but it has also led to more uncertainty about drugs’ clinical benefit and cost-effectiveness. How can this be addressed? In the last decade, many more cancer drugs have become available compared to what we’ve seen previously. This has led to more cancer treatment options, but it has also led to more uncertainty about drugs’ clinical benefit and cost-effectiveness. How can this be addressed?

by Mads Thomsen | Analysis | 2 December 2021

2 December 2021